Insider sales are quantitatively insignificant relative to market cap (0.03%) and partly tied to option exercises/vesting, but the cluster's proximity to a revenue-miss earnings release warrants monitoring for additional sales in coming weeks. Watch for any 8-K filings regarding Tyvaso competitive dynamics or ralinepag NDA updates.
How the stock moved after the report
⚠ Clustered NEUTRAL VIEWSTOCK ABOVE ENTRY AT T+60- T+0 · Aug 7 $538.84entry
- T+1 · 3mo ago −1.70%α −1.67% · $529.66
- T+5 · 3mo ago −7.26%α −7.66% · $499.73
- T+20 · 2mo ago −9.51%α −9.11% · $487.61
- T+60 · 15d ago +11.11%α +13.38% · $598.72
Price Chart
REPLAYWatch the reaction play outHow similar events traded
Executive Summary
United Therapeutics CEO Martine Rothblatt and EVP Paul Mahon collectively sold ~$490K in open-market shares within two days of the company's Q2 2026 earnings release, which showed a 2% YoY revenue miss ($783.3M vs. $804.6M consensus) but an EPS beat ($7.27 vs. $6.86). The sales follow option exercises and represent a small fraction of market cap, but the timing, right after a mixed earnings report with declining Tyvaso sales, raises watchfulness.
Key Financial Metrics
Key Facts
- CEO Rothblatt sold 4,895 open-market shares on Aug 5, 2026, for ~$2.5M (including sales after option exercises).
- EVP Mahon sold 8,300 open-market shares on Aug 6, 2026, for ~$4.3M (including sales after option exercises).
- Total open-market sales in cluster: ~$6.8M, representing 0.03% of $22.6B market cap, trivial proportionally.
- Q2 2026 revenue of $783.3M missed consensus by ~2.7% (down 2% YoY); EPS of $7.27 beat by 5.9%.
- Tyvaso Nebulized sales fell 18% YoY, partially offset by Tyvaso DPI growth.
- Insider cluster closed within 2 days of earnings, triggering AMPLIFIER cross-filing actuarial verdict (cluster-earnings-context + cluster-insider-trades).
Financial Impact
Total open-market insider sales of ~$6.8M (0.03% of market cap) are trivial in size; primary economic event is the mixed Q2 earnings with revenue miss but EPS beat.
Risk Factors
- Continued erosion of Tyvaso Nebulized sales could pressure top-line growth; Tyvaso DPI must accelerate to offset.
- Insiders selling after earnings may signal lack of confidence in near-term pipeline catalysts (ralinepag, IPF filing).
Market Snapshot
Investment Themes
Documents Analyzed
This report is based on 1 SEC document filed with EDGAR.
| Document | Accession Number |
|---|---|
| CLUSTER Data (Synthetic) | cluster-UTHR-1786082523840 |
Track record
123 reports on UTHR
4 of 9 bullish or bearish reports moved the stock their way by T+5. Best: +10.30% at T+20 after the Oct 14, 2026 report. 5 of 9 went positive at some point.
Filters
- Nov 16, 2026today Insider Cluster Neutral 3/10 Entry price pending
- Nov 13, 20263d ago Insider Cluster Bearish 4/10 Entry $597.50 Now $587.88 +1.61% settles Nov 23
- Nov 12, 20264d ago Insider Cluster Neutral 2/10 Entry $591.17 Now $587.88 −0.56% settles Nov 20
- Nov 10, 20266d ago Insider Cluster Neutral 2/10 Entry $595.66 Now $587.88 −1.31% settles Nov 18
- Nov 9, 20267d ago Insider Cluster Neutral 2/10 Entry $588.61 Now $587.88 −0.12% settles Nov 17
- Nov 9, 20267d ago 144 Neutral 2/10 Entry $588.61 Now $587.88 −0.12% settles Nov 17
- Nov 6, 202610d ago Insider Cluster Neutral 2/10 Entry $582.46 to $587.88 Now $587.88 +0.93% ▲ +0.93% +2.62% vs SPY
- Nov 5, 202611d ago Insider Cluster Neutral 2/10 Entry $562.02 to $591.17 Now $587.88 +4.60% ▲ +5.19% +2.59% vs SPY
- Nov 5, 202611d ago 144 Neutral 2/10 Entry $562.02 to $591.17 Now $587.88 +4.60% ▲ +5.19% +2.59% vs SPY
- Nov 4, 202612d ago SC 13G/A Neutral 2/10 Entry $565.72 to $593.31 Now $587.88 +3.92% ▲ +4.88% +1.59% vs SPY
US Market Status
Subscribe to SecBot
Get Real-Time SEC Filing Intelligence
Comprehensive SEC filing analysis delivered the moment filings hit EDGAR. Sentiment scoring, impact analysis, and actionable insights for every material event.
Create a free account Live analysis, Telegram alerts, watchlists and the MCP server for subscribers